Sage Therapeutics, Inc. (NASDAQ:SAGE) Expected to Post Quarterly Sales of $1.86 Million

Equities analysts forecast that Sage Therapeutics, Inc. (NASDAQ:SAGE) will announce sales of $1.86 million for the current fiscal quarter, according to Zacks. Nine analysts have made estimates for Sage Therapeutics’ earnings. The highest sales estimate is $2.80 million and the lowest is $500,000.00. Sage Therapeutics reported sales of $1.96 million during the same quarter last year, which suggests a negative year over year growth rate of 5.1%. The company is expected to announce its next earnings results before the market opens on Wednesday, February 24th.

According to Zacks, analysts expect that Sage Therapeutics will report full year sales of $7.04 million for the current fiscal year, with estimates ranging from $5.50 million to $8.67 million. For the next fiscal year, analysts forecast that the business will report sales of $170.37 million, with estimates ranging from $9.71 million to $900.10 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Sage Therapeutics.

SAGE has been the topic of a number of recent analyst reports. William Blair reiterated a “buy” rating on shares of Sage Therapeutics in a research report on Friday, December 4th. Morgan Stanley cut their target price on Sage Therapeutics from $85.00 to $83.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 1st. Bank of America raised their target price on Sage Therapeutics from $72.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, November 16th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell cut their price objective on Sage Therapeutics from $100.00 to $93.00 in a research report on Tuesday, December 1st. Finally, BMO Capital Markets cut Sage Therapeutics from an “outperform” rating to a “market perform” rating and set a $95.00 target price for the company. in a report on Friday, January 22nd. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.05.

A number of institutional investors and hedge funds have recently bought and sold shares of SAGE. Amundi Pioneer Asset Management Inc. boosted its position in Sage Therapeutics by 40.7% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock worth $21,704,000 after purchasing an additional 39,447 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in Sage Therapeutics during the third quarter worth $177,000. Candriam Luxembourg S.C.A. boosted its position in Sage Therapeutics by 3,632.5% during the third quarter. Candriam Luxembourg S.C.A. now owns 149,300 shares of the biopharmaceutical company’s stock worth $9,125,000 after purchasing an additional 145,300 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in shares of Sage Therapeutics by 6.7% in the third quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 7,170 shares of the biopharmaceutical company’s stock valued at $438,000 after acquiring an additional 450 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Sage Therapeutics in the third quarter valued at $1,211,000.

Sage Therapeutics stock traded up $0.42 during mid-day trading on Thursday, hitting $81.51. The company had a trading volume of 11,401 shares, compared to its average volume of 478,069. Sage Therapeutics has a 12-month low of $25.01 and a 12-month high of $98.39. The company’s fifty day moving average is $85.97 and its 200-day moving average is $71.71. The company has a market capitalization of $4.24 billion, a price-to-earnings ratio of -7.83 and a beta of 2.23.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases.

Further Reading: Resistance Level

Get a free copy of the Zacks research report on Sage Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.